Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 10, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	192	138	130	69	38	118
Market Cap Growth	142.01%	6.60%	87.08%	83.20%	-68.02%	143.47%
Enterprise Value	176	117	115	82	26	141
Last Close Price	2.56	1.88	1.78	1.37	0.83	3.63
PE Ratio	31.38	47.21	15.62	-	-	-
Forward PE	10.34	3.94	-	60.89	-	-
PS Ratio	3.09	2.59	1.98	1.46	0.99	1.88
PB Ratio	4.09	3.20	3.87	-6.52	-6.28	-4.38
P/TBV Ratio	4.09	3.20	3.87	-	-	-
P/FCF Ratio	-	18.73	-	-	-	-
P/OCF Ratio	-	15.96	-	-	-	-
EV/Sales Ratio	2.84	2.19	1.75	1.72	0.68	2.24
EV/EBITDA Ratio	18.35	22.35	9.86	-	-	35.08
EV/EBIT Ratio	21.40	29.80	10.98	-	-	51.93
EV/FCF Ratio	-	15.79	-	-	-	-
Debt / Equity Ratio	0.11	0.13	0.78	-3.15	-5.54	-2.38
Debt / EBITDA Ratio	0.47	0.81	2.00	-	-	11.94
Debt / FCF Ratio	-	0.75	-	-	-	-
Asset Turnover	0.73	0.68	0.93	0.74	0.54	1.11
Inventory Turnover	1.26	1.21	1.28	1.13	1.05	1.02
Quick Ratio	1.78	1.49	1.11	0.84	1.29	0.48
Current Ratio	2.72	2.35	1.54	1.38	1.86	0.64
Return on Equity (ROE)	15.99%	7.64%	72.50%	-	-	-
Return on Assets (ROA)	6.05%	3.10%	9.32%	-12.57%	-18.06%	2.99%
Return on Capital (ROIC)	9.35%	4.51%	15.81%	-32.36%	-39.47%	12.11%
Return on Capital Employed (ROCE)	15.10%	8.20%	26.90%	-	-	-
Earnings Yield	3.07%	2.12%	6.40%	-21.50%	-72.80%	-5.50%
FCF Yield	-1.69%	5.34%	-1.90%	-36.92%	-31.00%	-22.59%
Buyback Yield / Dilution	-14.25%	1.66%	-70.04%	-9.81%	-51.43%	-96.44%

Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q